{"id":184090,"date":"2025-12-10T03:14:10","date_gmt":"2025-12-10T03:14:10","guid":{"rendered":"https:\/\/www.newsbeep.com\/ie\/184090\/"},"modified":"2025-12-10T03:14:10","modified_gmt":"2025-12-10T03:14:10","slug":"1-major-factor-behind-the-healthcare-sectors-recent-surge","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/ie\/184090\/","title":{"rendered":"1 Major Factor Behind the Healthcare Sector’s Recent Surge"},"content":{"rendered":"\n

Eli Lilly’s GLP-1 drug became the world’s best-selling drug in Q3.<\/p>\n

Merck, Johnson & Johnson, AbbVie, and other companies are soaring on new drugs or the growth of existing ones.<\/p>\n

10 stocks we like better than Eli Lilly \u203a<\/a><\/p>\n

The healthcare sector<\/a> has vastly outperformed the broader market in recent weeks. The S&P 500 Health Care Sector index is up around 5.1% over the past month, while the broader S&P 500 index has climbed just about 2.3%.<\/p>\n

The primary factor behind this outperformance is blockbuster drugs<\/a>. The best-performing healthcare stocks in the sector are drug manufacturers, and they’ve been on fire of late.<\/p>\n

\"A Image source: Getty Images. <\/p>\n

Eli Lilly (NYSE: LLY) had a huge third quarter, and its GLP-1 medication — tirzepatide, which treats both type 2 diabetes and obesity — became the best-selling drug on the planet during the quarter. Lilly, the largest company in the sector by market cap, is up 9.1% over the past month.<\/p>\n

Johnson & Johnson (NYSE: JNJ) announced on Nov. 17 that it will acquire Halda Therapeutics, a clinical-stage biotechnology company. Halda has a proprietary platform to develop oral, targeted therapies for multiple types of solid tumors, particularly prostate cancer. J&J’s stock is up 8.6% over the past month.<\/p>\n

AbbVie (NYSE: ABBV) is another hot pharma stock. Sales of its Skyrizi, an immunology drug that treats conditions like psoriasis and arthritis, rose a whopping 46.8% to $4.7 billion during the third quarter. Sales of Rinvoq, a similar immunology drug, climbed 35.3% to nearly $2.2 billion. Management said it believes Rinvoq will hit $11 billion in annual revenue by 2027, and Skyrizi will reach the $20 billion mark. The stock has climbed 4.3% in a month.<\/p>\n

And drug giant Merck (NYSE: MRK) is up a whopping 18.2% over the past month. Quarterly sales of Keytruda, its blockbuster cancer drug, rose 10% from the same period a year ago and topped $8 billion for the first time.<\/p>\n

Those are a few of the major blockbuster drugs sending healthcare stocks higher, but there are many more.<\/p>\n

Before you buy stock in Eli Lilly, consider this:<\/p>\n

The Motley Fool Stock Advisor analyst team just identified what they believe are the\u00a010 best stocks<\/a> for investors to buy now\u2026 and Eli Lilly wasn\u2019t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.<\/p>\n

Consider when Netflix made this list on December 17, 2004… if you invested $1,000 at the time of our recommendation,\u00a0you\u2019d have $521,982!* Or when Nvidia made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you\u2019d have $1,137,459!*<\/p>\n","protected":false},"excerpt":{"rendered":"Eli Lilly’s GLP-1 drug became the world’s best-selling drug in Q3. Merck, Johnson & Johnson, AbbVie, and other…\n","protected":false},"author":2,"featured_media":184091,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[76472,79095,15862,12250,103,397,396,14356,61,60,14174,3058],"class_list":{"0":"post-184090","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-healthcare","8":"tag-abbvie","9":"tag-blockbuster-drugs","10":"tag-drug-manufacturers","11":"tag-eli-lilly","12":"tag-health","13":"tag-health-care","14":"tag-healthcare","15":"tag-healthcare-sector","16":"tag-ie","17":"tag-ireland","18":"tag-johnson-johnson","19":"tag-nyse"},"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts\/184090","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/comments?post=184090"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts\/184090\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/media\/184091"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/media?parent=184090"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/categories?post=184090"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/tags?post=184090"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}